ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) Short Interest Update

ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 7,100 shares, a drop of 17.4% from the January 31st total of 8,600 shares. Based on an average daily volume of 11,700 shares, the short-interest ratio is presently 0.6 days.

Institutional Investors Weigh In On ProShares UltraShort Nasdaq Biotechnology

An institutional investor recently bought a new position in ProShares UltraShort Nasdaq Biotechnology stock. Jane Street Group LLC bought a new position in shares of ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 10,520 shares of the company’s stock, valued at approximately $158,000. Jane Street Group LLC owned 4.78% of ProShares UltraShort Nasdaq Biotechnology at the end of the most recent quarter.

ProShares UltraShort Nasdaq Biotechnology Trading Up 0.8 %

Shares of NASDAQ:BIS traded up $0.13 during trading on Thursday, reaching $16.66. The stock had a trading volume of 3,607 shares, compared to its average volume of 10,591. The stock has a fifty day simple moving average of $17.14 and a two-hundred day simple moving average of $16.15. ProShares UltraShort Nasdaq Biotechnology has a 52 week low of $14.05 and a 52 week high of $21.10.

ProShares UltraShort Nasdaq Biotechnology Increases Dividend

The firm also recently declared a dividend, which was paid on Tuesday, December 31st. Stockholders of record on Monday, December 23rd were issued a dividend of $0.2064 per share. The ex-dividend date of this dividend was Monday, December 23rd. This is a positive change from ProShares UltraShort Nasdaq Biotechnology’s previous dividend of $0.15.

ProShares UltraShort Nasdaq Biotechnology Company Profile

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.